Hypera buys Buscopan and Buscofen brands for R$ 1.13 billion

After disclosing the purchase of products from the Brands Buscopan and Buscofem, which were part of the portfolio of the pharmaceutical company Boehringer Ingelheim, The Brazilian Hypera leads the highs of B3, the Brazilian Stock Exchange, on Wednesday, 18. The Brazilian, previously called Hypermarcas, announced on Wednesday the acquisition of the popular family of medicines, in a business of R $ 1.13 billion. Investors have received the news well, which tends to extend the company's distance to competitors. Today, Hypera Farma is the largest pharmaceutical company in the country. Around 3:15 p.m., the company's shares were trading at R$ 34.71, up 3.24%. No revenue Buscopan is "the leading brand in the antispasmodic segment in Brazil, and the Buscopan and Buscofem family the second largest franchise in the OTC market in Brazil," said Hypera, the largest Brazilian company in the pharmaceutical sector, referring to drugs that do not require a medical prescription. According to the company, the acquisition is part of the group's strategy, which in recent years has focused on the pharmaceutical segment, of seeking strengthening in the market of products that do not need revenue. The acquisition was announced a few weeks after Hypera's board of directors approved issue of R$ 800 million in 6-year-old debentures. Debentures are fixed-income debt securities launched by companies in the financial market. The holders of these roles have the commitment to return the investment, plus a premium, usually fixed by di interest, a rate that follows hand in hand with Selic. At the end of October, Hypera's president, Breno de Oliveira, said when asked about possible acquisitions, that the company focused on organic growth, but that the company's debt situation was quite comfortable.